Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perhexiline in Symptomatic Hypertrophic Cardiomyopathy
NCT04426578Phase 2Unknown
- Sponsor
- Flinders University
- Start
- Dec 2020
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Perhexiline Arm with Placebo Arm (2 arms). Primary endpoint: Change in Left Ventricular Hypertrophy at 12 months. Status: unknown.
02
Drugs
perhexiline
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT04426578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04426578.